Skip to main content
TipRanks
Go Ultimate75% OFF

Carisma Therapeutics (CARM) Stock Statistics & Valuation Metrics

1,711 Followers

Total Valuation

Carisma Therapeutics has a market cap or net worth of $8,369.00. The enterprise value is -$1.18T.

Market Cap
$8,369.00
Enterprise Value
-$1.18T

Share Statistics

Carisma Therapeutics has 41,845,078 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
41,845,078
Owned by Insiders
―
Owned by Institutions
0.26%

Financial Efficiency

Carisma Therapeutics’s return on equity (ROE) is 2.17 and return on invested capital (ROIC) is -385.25%.

Return on Equity (ROE)
2.17
Return on Assets (ROA)
-1.99
Return on Invested Capital (ROIC)
-385.25%
Return on Capital Employed (ROCE)
-4.32
Revenue Per Employee
426.78K
Profits Per Employee
-1.31M
Employee Count
46
Asset Turnover
0.64
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Carisma Therapeutics is 0.00. Carisma Therapeutics’s PEG ratio is 0.00.

PE Ratio
0.00
PS Ratio
0.00
PB Ratio
-0.01
Price to FCF
-0.00
Price to Operating Cash Flow
-0.00
PEG Ratio
0.00

Income Statement

In the last 12 months, Carisma Therapeutics had revenue of 19.63M and earned -60.48M in profits. Earnings per share was -1.46.

Revenue
19.63M
Gross Profit
-40.04M
Operating Income
-62.18M
Pretax Income
-60.48M
Net Income
-60.48M
EBITDA
-56.83M
Earnings Per Share (EPS)
-1.46

Cash Flow

In the last 12 months, operating cash flow was -22.41M and capital expenditures 0, giving a free cash flow of -22.41M billion.

Operating Cash Flow
-22.41M
Free Cash Flow
-22.41M
Free Cash Flow per Share
-0.10

Dividends & Yields

Carisma Therapeutics pays an annual dividend of $0.36, resulting in a dividend yield of ―

Dividend Per Share
$0.36
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-47747.64%
Earnings Yield
418097.54%

Stock Price Statistics

Beta
8.07
52-Week Price Change
-42.86%
50-Day Moving Average
0.03
200-Day Moving Average
0.04
Relative Strength Index (RSI)
―
Average Volume (3m)
1,220

Important Dates

Carisma Therapeutics upcoming earnings date is ―, TBA (Confirmed).

Last Earnings Date
Nov 06, 2025
Next Earnings Date
―
Ex-Dividend Date
Mar 08, 2023

Financial Position

Carisma Therapeutics as a current ratio of 1.48, with Debt / Equity ratio of -8.89%

Current Ratio
1.48
Quick Ratio
1.48
Debt to Market Cap
0.00
Net Debt to EBITDA
0.27
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Carisma Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Carisma Therapeutics EV to EBITDA ratio is -0.05, with an EV/FCF ratio of 0.50.

EV to Sales
-0.04
EV to EBITDA
-0.05
EV to Free Cash Flow
0.50
EV to Operating Cash Flow
0.50

Balance Sheet

Carisma Therapeutics has $2.78M in cash and marketable securities with $762.00K in debt, giving a net cash position of $2.02M billion.

Cash & Marketable Securities
$2.78M
Total Debt
$762.00K
Net Cash
$2.02M
Net Cash Per Share
$0.05
Tangible Book Value Per Share
-$0.02

Margins

Gross margin is 99.21%, with operating margin of 84.06%, and net profit margin of 77.22%.

Gross Margin
99.21%
Operating Margin
84.06%
Pretax Margin
77.22%
Net Profit Margin
77.22%
EBITDA Margin
86.84%
EBIT Margin
86.05%

Scores

Smart Score
―
AI Score
40